These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11013715)

  • 1. Screening and testing for endocrine disrupters.
    Erickson B
    Anal Chem; 1998 Aug; 70(15):528A-532A. PubMed ID: 11013715
    [No Abstract]   [Full Text] [Related]  

  • 2. Screening chemicals for thyroid-disrupting activity: A critical comparison of mammalian and amphibian models.
    Pickford DB
    Crit Rev Toxicol; 2010 Nov; 40(10):845-92. PubMed ID: 20684730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xenoendocrine disrupters-tiered screening and testing: filling key data gaps.
    Gray LE; Ostby J; Wilson V; Lambright C; Bobseine K; Hartig P; Hotchkiss A; Wolf C; Furr J; Price M; Parks L; Cooper RL; Stoker TE; Laws SC; Degitz SJ; Jensen KM; Kahl MD; Korte JJ; Makynen EA; Tietge JE; Ankley GT
    Toxicology; 2002 Dec; 181-182():371-82. PubMed ID: 12505339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use and acceptance of Other Scientifically Relevant Information (OSRI) in the U.S. Environmental Protection Agency (EPA) Endocrine Disruptor Screening Program.
    Bishop PL; Willett CE
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):3-22. PubMed ID: 24151143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introduction to "screening for endocrine activity-experiences with the US EPA's endocrine disruptor screening program and future considerations".
    Marty S
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):1-2. PubMed ID: 24510782
    [No Abstract]   [Full Text] [Related]  

  • 6. Analysis of EPA's endocrine screening battery and recommendations for further review.
    Schapaugh AW; McFadden LG; Zorrilla LM; Geter DR; Stuchal LD; Sunger N; Borgert CJ
    Regul Toxicol Pharmacol; 2015 Aug; 72(3):552-61. PubMed ID: 26044367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypothesis-driven weight of evidence framework for evaluating data within the US EPA's Endocrine Disruptor Screening Program.
    Borgert CJ; Mihaich EM; Ortego LS; Bentley KS; Holmes CM; Levine SL; Becker RA
    Regul Toxicol Pharmacol; 2011 Nov; 61(2):185-91. PubMed ID: 21803110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Key learnings from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 in vitro assays.
    LeBaron MJ; Coady KK; O'Connor JC; Nabb DL; Markell LK; Snajdr S; Sue Marty M
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):23-42. PubMed ID: 24515815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of vitellogenin assay for endocrine disrupters using medaka (Oryzias latipes).
    Nozaka T; Abe T; Matsuura T; Sakamoto T; Nakano N; Maeda M; Kobayashi K
    Environ Sci; 2004; 11(2):99-121. PubMed ID: 15746892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of Adverse Outcome Pathways to U.S. EPA's Endocrine Disruptor Screening Program.
    Browne P; Noyes PD; Casey WM; Dix DJ
    Environ Health Perspect; 2017 Sep; 125(9):096001. PubMed ID: 28934726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chlorpyrifos: weight of evidence evaluation of potential interaction with the estrogen, androgen, or thyroid pathways.
    Juberg DR; Gehen SC; Coady KK; LeBaron MJ; Kramer VJ; Lu H; Marty MS
    Regul Toxicol Pharmacol; 2013 Aug; 66(3):249-63. PubMed ID: 23524272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The FQPA: a challenge for science policy and pesticide regulation.
    Scheuplein RJ; Byrd DM
    Regul Toxicol Pharmacol; 2000 Jun; 31(3):248-66. PubMed ID: 10915584
    [No Abstract]   [Full Text] [Related]  

  • 13. Utility of a juvenile fathead minnow screening assay for detecting (anti-)estrogenic substances.
    Panter GH; Hutchinson TH; Länge R; Lye CM; Sumpter JP; Zerulla M; Tyler CR
    Environ Toxicol Chem; 2002 Feb; 21(2):319-26. PubMed ID: 11833800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Policy reforms to update chemical safety testing.
    Nel AE; Malloy TF
    Science; 2017 Mar; 355(6329):1016-1018. PubMed ID: 28280165
    [No Abstract]   [Full Text] [Related]  

  • 15. Advances in EDC testing.
    J Environ Monit; 2000 Dec; 2(6):97N. PubMed ID: 11296775
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of the laboratory rat as a model in endocrine disruptor screening and testing.
    Gray LE; Wilson V; Noriega N; Lambright C; Furr J; Stoker TE; Laws SC; Goldman J; Cooper RL; Foster PM
    ILAR J; 2004; 45(4):425-37. PubMed ID: 15454681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine disruptor risk characterization: an EPA perspective.
    Fenner-Crisp PA
    Regul Toxicol Pharmacol; 1997 Aug; 26(1 Pt 1):70-3. PubMed ID: 9339482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approaches to the assessment of toxicity data with endpoints related to endocrine disruption.
    Harvey PW; Johnson I
    J Appl Toxicol; 2002; 22(4):241-7. PubMed ID: 12210541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine-disrupting chemicals probed as potential pathways to illness.
    Trubo R
    JAMA; 2005 Jul; 294(3):291-3. PubMed ID: 16030264
    [No Abstract]   [Full Text] [Related]  

  • 20. A novel framework for interpretation of data from the fish short-term reproduction assay (FSTRA) for the detection of endocrine-disrupting chemicals.
    Ankley GT; Jensen KM
    Environ Toxicol Chem; 2014 Nov; 33(11):2529-40. PubMed ID: 25098918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.